Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[5-(5-fluoro-3-pyridinyl)-2-[[3-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-, (1S,2S,3R,4R)- manufacturers
- IRAK4-IN-21
-
- $2590.00
-
2026-04-21
- CAS:2170694-04-7
- Purity:
- Supply Ability: 10g
|
| | Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[5-(5-fluoro-3-pyridinyl)-2-[[3-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-, (1S,2S,3R,4R)- Basic information |
| Product Name: | Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[5-(5-fluoro-3-pyridinyl)-2-[[3-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-, (1S,2S,3R,4R)- | | Synonyms: | Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[5-(5-fluoro-3-pyridinyl)-2-[[3-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-, (1S,2S,3R,4R)-;IRAK4-IN-21 | | CAS: | 2170694-04-7 | | MF: | C28H28FN7O2 | | MW: | 513.57 | | EINECS: | | | Product Categories: | | | Mol File: | 2170694-04-7.mol | ![Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[5-(5-fluoro-3-pyridinyl)-2-[[3-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-, (1S,2S,3R,4R)- Structure](CAS/20210305/GIF/2170694-04-7.gif) |
| | Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[5-(5-fluoro-3-pyridinyl)-2-[[3-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-, (1S,2S,3R,4R)- Chemical Properties |
| Boiling point | 827.1±75.0 °C(Predicted) | | density | 1.409±0.06 g/cm3(Predicted) | | pka | 16.25±0.40(Predicted) | | form | Solid | | color | White to off-white |
| | Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[5-(5-fluoro-3-pyridinyl)-2-[[3-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-, (1S,2S,3R,4R)- Usage And Synthesis |
| Uses | IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis[1]. | | in vivo | IRAK4-IN-21 (75 mg/kg; p.o.; single) shows moderate efficacy in acute animal model studies for the inhibition of IL-6 production[1]. | Animal Model: | BALB/c mice (acute mouse model; IL-1β-stimulated)[1]. | | Dosage: | 75 mg/kg | | Administration: | Oral administration; single (pre-treat). | | Result: | Showed 54% inhibition of IL-6, plasma concentrations was 2877 ng/mL at 0.5 h and 496 ng/mL at 2 h. |
| | References | [1] Chen Y, et al. Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors. ACS Med Chem Lett. 2022 Apr 4;13(4):714-719. DOI:10.1021/acsmedchemlett.2c00056 |
| | Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[5-(5-fluoro-3-pyridinyl)-2-[[3-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-, (1S,2S,3R,4R)- Preparation Products And Raw materials |
|